Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
KangaBio logo — Pioneering novel therapies to enhance treatment effectivenes...

KangaBio

Pioneering novel therapies to enhance treatment effectiveness and reduce side effects for critical medical conditions.

Founded 2021 Seed Total: $100.00M Health Care, Pharmaceutical

General Information

Company Name KangaBio
Founded Year 2021
Industries Health Care, Pharmaceutical
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with KangaBio. To contact KangaBio, visit kangabio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About KangaBio

KangaBio is a biotech startup founded in 2021 with a focus on pioneering novel therapies to enhance treatment effectiveness and reduce side effects for critical medical conditions. The company is dedicated to addressing unmet medical needs by developing prodrugs of immune-stimulating medications and other multi-specific biologics to reduce toxicities and improve treatment efficacy for established targets. In June 2023, KangaBio secured a CNY100.00M investment in a Seed Round, with participation from prominent investors including Teda Venture Capital, TaiKun Fund, and Dingfu Investment. The startup operates within the Health Care and Pharmaceutical industries, demonstrating potential for significant impact in the realm of healthcare innovation.

Taxonomy: biotech, novel therapies, medicine development, prodrugs, immune-stimulating medications, biologics, medical conditions, treatment effectiveness, side effects reduction, toxicity minimization, treatment efficacy, unmet medical needs

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round CNY100.00M 3
Teda Venture Capital
Teda Venture Capital, TaiKun Fund +1
27 Jun 2023

KangaBio Alternatives & Competitors

View All Alternatives
KangaBio vs
浙江时迈药业有限公司
浙江时迈药业有限公司 China

以患者和临床需求为己任

Series A
4 employees
Biotechnology, Health Care
KangaBio vs
CytoAgents, Inc
CytoAgents, Inc United States

Calming the Cytokine Storm, Rebalancing the Immune System. Accessible treatment for multiple areas...

Series A
10 employees
Biotechnology, Health Care
KangaBio vs
Ractigen Therapeutics
Ractigen Therapeutics China

Turn on genes and turn off diseases

Series A
18 employees
Health Care, Pharmaceutical
View all alternatives

FAQ About KangaBio

Pioneering novel therapies to enhance treatment effectiveness and reduce side effects for critical medical conditions.
KangaBio was founded in 2021.
KangaBio operates in Health Care and Pharmaceutical. Its work centres on biotech, novel therapies, medicine development and prodrugs.
KangaBio has completed 1 funding round, raising a total of $100.00M. The latest funding stage is Seed.
Top alternatives and competitors to KangaBio include 浙江时迈药业有限公司, CytoAgents, Inc, Ractigen Therapeutics, Chordia Therapeutics Inc, Carrick Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
KangaBio and 浙江时迈药业有限公司 are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for KangaBio, https://bouncewatch.com/company/kangabio, updated 11 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes